X-twitter Linkedin Facebook-f Vimeo

Nuformix updates Registered Office and Company Secretary

Nuformix plc

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that it has changed its registered office to C/O Arch Law Limited, Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ with immediate effect.

The Board is also pleased to announce that it has appointed Shaun Zulafqar as Company Secretary with immediate effect.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:
Preferred Source

Latest Company News

NFX

Nuformix Dr Dan Gooding on positive NXP002 study results and next steps

Nuformix says new preclinical results for inhaled NXP002 support its development as a potential treatment for idiopathic pulmonary fibrosis, showing lung concentrations in a therapeutic range, target pathway engagement and evidence of a viable safety window. The company is now advancing target identification work, planning toxicology studies and continuing partnering discussions ahead of the European Respiratory Society Congress.
NFX

Nuformix appoints Tim Metcalfe as Non-Executive Chairman

Nuformix has appointed Tim Metcalfe as non-executive chairman, with Julian Gilbert stepping down from the board for personal reasons.
Nuformix plc

Nuformix adds new preclinical support for NXP002

Nuformix has reported encouraging inhalation data for NXP002 as it prepares for further preclinical development and potential licensing discussions.
Nuformix Interview

Nuformix Plc NXP002 Data Strengthens Path Towards Toxicology and Partnering (video)

Dr Dan Gooding discusses therapeutically relevant lung exposure, fibrosis-related pathway engagement, the potential therapeutic window, toxicology planning and the company’s continuing discussions with prospective pharma partners.
NFX

Nuformix reports positive NXP002 inhalation study results

Nuformix has reported positive inhaled NXP002 preclinical data, supporting pulmonary exposure, target engagement and further development planning.
Nuformix plc

Pulmonary fibrosis care needs support a long-term treatment market

Pulmonary fibrosis creates long-term demand for treatments, respiratory equipment and patient-support services as care needs increase over time.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

BrokersTalk

View all Broker Talk

FTSE 100 News

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple